KEYNOTE-604 Final Analysis: Addition of Pembrolizumab to Etoposide and Platinum in Extensive-Stage SCLC

May 29-31, 2020; Online at meetings.asco.org/am
Pembrolizumab added to first-line therapy with etoposide and platinum chemotherapy for extensive-stage SCLC significantly improved PFS in the final analysis of KEYNOTE-604.
Format: Microsoft PowerPoint (.ppt)
File Size: 310 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Related Content

Phase I trials of EGFR/HER2 inhibitor DZD9008 in patients with advanced NSCLC and EGFR ex20ins mutations, from WCLC 2021 as reported by Clinical Care Options (CCO)

Released: September 20, 2021

Phase II ATEZO-BRAIN evaluating atezolizumab plus carboplatin/pemetrexed in advanced NSCLC with untreated brain metastases, from WCLC2021 as reported by Clinical Care Options (CCO)

Released: September 20, 2021

Download these slides for an overview of the evolving immunotherapy landscape for advanced or metastatic NSCLC, from CCO

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Download these slides for an overview of the evolving immunotherapy landscape for early-stage resectable and stage III unresectable NSCLC, from CCO

person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue